Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Amiselimod

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bausch Health Reports R&D Updates Amiselimod Data At Conferences
    Bausch Health Reports R&D Updates Amiselimod Data At Conferences

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877482&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share
    Salix Presents Phase 2 Amiselimod UC Data At DDW 2024
    Salix Presents Phase 2 Amiselimod UC Data At DDW 2024

    17 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/864258/salix-to-present-late-breaking-data-from-phase-2-trial-of-amiselimod-in-active-ulcerative-colitis-at-digestive-disease-week-2024

    ACCESSWIRE
    17 May 2024
    Share Share
    Bausch Announces Positive Results From Phase 2 Study Evaluating Amiselimod
    Bausch Announces Positive Results From Phase 2 Study Evaluating Amiselimod

    21 Dec 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=819070&lang=en

    ACCESSWIRE
    21 Dec 2023
    Share Share